CATALOGO DEI PRODOTTI DELLA RICERCA

FRACASSO, Giulio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.215
EU - Europa 5.610
AS - Asia 4.445
SA - Sud America 566
AF - Africa 109
OC - Oceania 8
Continente sconosciuto - Info sul continente non disponibili 5
Totale 16.958
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.055
RU - Federazione Russa 2.030
SG - Singapore 1.757
CN - Cina 1.293
GB - Regno Unito 1.277
IT - Italia 510
BR - Brasile 466
VN - Vietnam 431
HK - Hong Kong 376
FR - Francia 323
SE - Svezia 322
IE - Irlanda 296
DE - Germania 278
FI - Finlandia 240
KR - Corea 151
CA - Canada 93
UA - Ucraina 83
IN - India 76
TR - Turchia 58
JP - Giappone 54
MX - Messico 48
NL - Olanda 46
AR - Argentina 41
BD - Bangladesh 38
PL - Polonia 38
ID - Indonesia 35
ES - Italia 32
IQ - Iraq 30
BE - Belgio 29
NG - Nigeria 26
ZA - Sudafrica 26
IR - Iran 23
PK - Pakistan 20
EC - Ecuador 13
SA - Arabia Saudita 13
AT - Austria 12
CH - Svizzera 11
LT - Lituania 11
MA - Marocco 11
PH - Filippine 11
UZ - Uzbekistan 11
AE - Emirati Arabi Uniti 10
VE - Venezuela 10
GR - Grecia 9
CO - Colombia 8
EG - Egitto 8
UY - Uruguay 8
BY - Bielorussia 7
HR - Croazia 7
JO - Giordania 7
PE - Perù 7
AU - Australia 6
AZ - Azerbaigian 6
CL - Cile 6
MY - Malesia 6
PT - Portogallo 6
PY - Paraguay 6
TN - Tunisia 6
AL - Albania 5
DZ - Algeria 5
KE - Kenya 5
RO - Romania 5
TW - Taiwan 5
DK - Danimarca 4
DO - Repubblica Dominicana 4
ET - Etiopia 4
KW - Kuwait 4
LV - Lettonia 4
PA - Panama 4
BJ - Benin 3
CZ - Repubblica Ceca 3
EU - Europa 3
HN - Honduras 3
IL - Israele 3
JM - Giamaica 3
KZ - Kazakistan 3
LU - Lussemburgo 3
NP - Nepal 3
OM - Oman 3
SN - Senegal 3
TG - Togo 3
A2 - ???statistics.table.value.countryCode.A2??? 2
BA - Bosnia-Erzegovina 2
BG - Bulgaria 2
CI - Costa d'Avorio 2
CM - Camerun 2
CR - Costa Rica 2
CY - Cipro 2
KG - Kirghizistan 2
MD - Moldavia 2
NO - Norvegia 2
QA - Qatar 2
RS - Serbia 2
SI - Slovenia 2
SK - Slovacchia (Repubblica Slovacca) 2
SY - Repubblica araba siriana 2
TH - Thailandia 2
AM - Armenia 1
BO - Bolivia 1
BS - Bahamas 1
Totale 16.937
Salva come PNG Salva come JPEG
Città #
Southend 1.073
Singapore 924
Moscow 701
Chandler 644
Ashburn 633
Dallas 630
Jacksonville 564
San Jose 543
Woodbridge 408
Hong Kong 361
Dublin 293
Ann Arbor 281
Verona 260
Beijing 240
Houston 206
The Dalles 177
Ho Chi Minh City 134
Lawrence 106
Princeton 106
New York 105
Wilmington 100
Los Angeles 94
Jinan 92
Hanoi 84
Nanjing 80
Shenyang 65
Tianjin 64
Buffalo 63
Helsinki 63
Tokyo 50
Hebei 49
São Paulo 48
Santa Clara 45
Changsha 43
Columbus 42
Munich 41
Sindelfingen 39
Seoul 37
Zhengzhou 37
Dong Ket 35
Orem 35
Milan 34
Chennai 33
London 33
Seattle 32
Warsaw 30
Boardman 29
Brussels 29
Montreal 29
Guangzhou 28
Redondo Beach 28
Jakarta 27
Haikou 25
Ningbo 25
Hangzhou 24
Jiaxing 24
Abuja 23
Denver 23
Redwood City 23
Frankfurt am Main 22
San Francisco 22
Taizhou 22
Johannesburg 21
Taiyuan 21
Atlanta 20
Stockholm 20
Turku 20
Brooklyn 19
Da Nang 19
Nanchang 19
Amsterdam 18
Council Bluffs 18
Norwalk 18
Lancaster 17
Paris 17
Bologna 16
Chicago 16
Fuzhou 16
Rio de Janeiro 15
Boston 14
Redmond 14
Falkenstein 13
Manchester 13
Montréal 13
Padova 13
Shanghai 13
Toronto 13
Mexico City 12
Nuremberg 12
Poplar 12
Tashkent 11
Barnet 10
Biên Hòa 10
Haiphong 10
Brasília 9
Lappeenranta 9
Phoenix 9
Rome 9
Vancouver 9
Ankara 8
Totale 10.706
Salva come PNG Salva come JPEG
Nome #
Anti PSMA immunotoxins activity against prostate cancer cell lines. 287
Anti-tumor effects of toxins targeted to the prostate specific membrane antigen. 271
Immunotoxins and other conjugates: preparation and general characteristics. 252
Anti-PSMA-Immunotoxins: a new therapeutical strategy for selective targeting of toxins to prostate cancer cells. 246
Apical transport and folding of prostate-specific membrane antigen occurs independent of glycan processing. 235
Anti PSCA Monoclonal Antibody and scFv-Fragment for Immunotherapy of Prostate, Pancreatic and Bladder Carcinoma 235
Filamin A-mediated interaction of Prostate Specific Membrane Antigen (PSMA) with beta1 integrin regulates survival of advanced prostate cancer cells 232
A SERRS/MRI multimodal contrast agent based on naked Au nanoparticles functionalized with a Gd(iii) loaded PEG polymer for tumor imaging and localized hyperthermia 229
Characterization of a new anti PSCA monoclonal antibody and scFv fragment for diagnosis and immunotherapy of prostate, pancreatic and bladder carcinoma. 223
Reductive activation of ricin and ricin-A chain immunotoxins by Protein Disulfide Isomerase and Thioredoxin Reductase system. 217
Feasibility of telomerase-specific adoptive T-cell therapy for B-cell chronic lymphocytic leukemia and solid malignancies 216
Cooperation of Prostate Specific Membrane Antigen with beta 1 integrin promotes the survival of aggressive prostate cancer cells 215
Prostate-specific membrane antigen (PSMA) assembles a macromolecular complex regulating growth and survival of prostate cancer cells "in vitro" and correlating with progression "in vivo" 214
A single-chain fragment against prostate specific membrane antigen as a tool to build theranostic reagents for prostate cancer 210
Anti-prostate specific membrane antigen targeted gold nanoparticles in tumor therapy and diagnosis 208
Anticorpo monoclonale isolato o suo frammento legante l'antigene specifico di membrana della prostata, suoi coniugati e suoi usi 208
Production of a biotinylated anti-PSMA single-chain antibody fragment (scFv) for imaging and radioimmunotherapy 204
EpCAM a possible target for immunotoxin treatments of PSMA positive and negative prostate cancer cells 203
Characterization of In-111-labeled site-specifically conjugated anti-PSMA antibody-drug conjugates for treatment of PSMA-expressing tumors 202
A dominant linear B-cell epitope of ricin A-chain is the target of a neutralizing antibody response in Hodgkin's lymphoma patients treated with an anti-CD25 immunotoxin 201
Biodistribution of In-111-labeled D2B IgG, F(ab’)2 and Fab fragments in nude mice bearing human prostate cancer xenografts 196
Ingegnerizzazione di un vettore per espressione di frammenti anticorpali (scFv) biotinilati in procarioti, purificazione ed analisi funzionale 192
Induction of immunosuppressive functions and NF-κB by FLIP in monocytes 191
The prostate specific membrane antigen regulates the expression of IL-6 and CCL5 in prostate tumor cells by activating the MAPK pathways. 191
Investigation of Properties of Anti-Prostate Specific Membrane Antigen-targeted Gold Nanoparticles as Drug Carriers in Tumor Therapy 190
Targeted Killing of Prostate Cancer Cells using Antibody-Drug conjugated Carbon Nanohorns 190
The prostate specific membrane antigen regulates the expression of IL-6 and CCL-5 in prostate tumour cells by activating the MAPK pathways 184
Protein Disulfide Isomerase and Thioredoxin Reductase: a ricin disulfide reducing system in the endoplasmic reticulum. 183
Tumor Targeting with Guided Silica Nanopartilces for Prostate Cancer Therapy 183
Acute sarcomeric M-Line Disease associated with ATP synthase subunit α autoantibodies in ankylosing spondylitis 183
Produzione e validazione preclinica di un anticorpo anti-PSMA per diagnostica ed immunotargeting 178
N-terminal deletion affetcs catalytic activity of saporin toxin. 176
Top-down synthesis of multifunctional iron oxide nanoparticles for macrophage labelling and manipulation 176
Generazione di nuovi anticorpi anti prostate stem cell antigen (PSCA) e loro caratterizzazione al fine di un futuro utilizzo nella terapia e nella diagnosi dei carcinomi prostatico, pancreatico e della vescica 175
Cloning and characterisation of canine prostate-specific membrane antigen 175
Plasmonic Nanostructures for SERRS Multiplexed Identification of Tumor-Associated Antigens 175
The Filamin A-mediated cooperation of Prostate Specific Membrane Antigen (PSMA) with beta1 integrin promotes the survival of aggressive prostate cancer cells. 175
An electrochemiluminescent-supramolecular approach to sarcosine detection for early diagnosis of prostate cancer. 174
Discriminatory role of detergent-resistant membranes in the dimerization and endocytosis of prostate-specific membrane antigen 173
Characterization of an In-111-labeled anti-PSMA antibody-photosensitizer conjugate for targeted photodynamic therapy of PSMA-expressing tumors 173
Targeted delivery of photosensitizers: efficacy and selectivity issues revealed by multifunctional ORMOSIL nanovectors in cellular systems 172
Prostate Specific Membrane Antigen (PSMA) associates with Filamin A, beta1 integrin, pp130CAS and pSrc thus regulating the activation of beta1 integrin and the survival of prostate cancer cells. 172
Constitutive activation of p38 and ERK1/2 MAPKs in epithelial cells of myasthenic thymus leads to IL-6 and RANTES overexpression: effects on survival and migration of peripheral T and B cells. 171
Reductive activation of ricin and ricin A-chain immunotoxins by protein disulfide isomerase and thioredoxin reductase. 170
Prostate-specific membrane antigen associates already in the endoplasmic reticulum with lipid microdomains 167
Highly sensitive electrochemiluminescence detection of a prostate cancer biomarker 164
Neutralization of NET-associated human ARG1 enhances cancer immunotherapy 163
Magneto-Plasmonic Au-Fe alloy nanoparticles designed for multimodal SERS-MRI-CT imaging 163
Pegylated silica nanoparticles: cytotoxicity and macrophage uptake 161
Anti-PSMA CAR-engineered NK-92 Cells: An Off-the-shelf Cell Therapy for Prostate Cancer 161
Self-potentiation of ligand-toxin conjugates containing ricin A chain fused with viral structures 161
Identification of Ricin A chain HLA II-restricted epitopes by human T-cell clones. 157
Isolated monoclonal antibody or fragment thereof binding prostate specific membrane antigen, conjugates and uses thereof 157
Characterization of Site-Specifically Conjugated Monomethyl Auristatin E- and Duocarmycin-Based Anti-PSMA Antibody-Drug Conjugates for Treatment of PSMA-Expressing Tumors 157
Prostate-specific membrane antigen (PSMA) associates early in the endoplasmic reticulum with lipid microdomains 153
Comparative analysis of monoclonal antibodies against prostate-specific membrane antigen (PSMA) 152
Expression of myelin basic protein (MBP) epitopes in human non-neural cells revealed by two anti-MBP IgM monoclonal antibodies 151
SERS IMAGING OF CANCER CELLS WITH ANTIBODY FUNCTIONALIZED GOLD NANOPARTICLES 150
Targeted Silica Nanoparticles for PhotoDynamic Therapy (PDT) 149
Parallel optical read-out of micromechanical pillars applied to prostate specific membrane antigen detection 148
Design and Evaluation of 223Ra-Labeled and Anti-{PSMA} Targeted {NaA} Nanozeolites for Prostate Cancer Therapy{ extendash}Part I 147
Heterogeneous response of individual multicellular tumour spheroids to immunotoxins and ricin toxin 141
Polymer-coated silver-iron nanoparticles as efficient and biodegradable MRI contrast agents 141
Gangliosides act as onconeural antigens in paraneoplastic neuropathies. 140
Identification of ricin A-chain HLA class II-restricted epitopes by human T-cell clones 139
Targeting human prostate cancer with (111) In-labeled D2B IgG, F(ab')2 and Fab fragments in nude mice with PSMA-expressing xenografts. 135
SERS labels for quantitative assays: application to the quantification of gold nanoparticles uptaken by macrophage cells 135
Laser generated gold nanocorals with broadband plasmon absorption for photothermal applications 131
Safe Core-Satellite Magneto-Plasmonic Nanostructures for Efficient Targeting and Photothermal Treatment of Tumor Cells 127
Engineered Human Nanoferritin Bearing the Drug Genz-644282 for Cancer Therapy 127
High activity and low toxicity of a novel CD71-targeting nanotherapeutic named The-0504 on preclinical models of several human aggressive tumors 127
Pharmacokinetics of intrathecal transferrin-ricin A chain immunotoxins 126
In vivo imaging of prostate cancer using an anti-PSMA scFv fragment as a probe 126
SERRS Multiplexing with Multivalent Nanostructures for the Identification and Enumeration of Epithelial and Mesenchymal Cells 125
Simple and Rapid Non-Enzymatic Procedure Allows the Isolation of Structurally Preserved Connective Tissue Micro-Fragments Enriched with SVF 125
Effect of therapeutic macromolecules in spheroids 124
Liposomes derivatized with multimeric copies of KCCYSL peptide as targeting agents for HER-2-overexpressing tumor cells 124
Mitoxantrone-loaded nanoferritin slows tumor growth and improves the overall survival rate in a subcutaneous pancreatic cancer mouse model 123
Therapeutic Efficacy of the Novel Stimuli-Sensitive Nano-Ferritins Containing Doxorubicin in a Head and Neck Cancer Model 122
PSMA-Specific CAR-Engineered T Cells Eradicate Disseminated Prostate Cancer in Preclinical Models 120
Improved method for carbohydrate-deficient transferrin determination in human serum by capillary zone electrophoresis 119
Genetic grafting of membrane-acting peptides to the cytotoxin dianthin augments its ability to de-stabilize lipid bilayers and enhances its cytotoxic potential as the component of transferrin-toxin conjugates. 119
The presence of glutamate residues on the PAS sequence of the stimuli-sensitive nano-ferritin improves in vivo biodistribution and mitoxantrone encapsulation homogeneity 119
Prostate-specific membrane antigen routing to the cell surface implicates an early association step in the endoplasmic reticulum with lipid microdomains. 117
Ribosome-inactivating protein-containing conjugates for therapeutic use 116
G Protein-Coupled Receptors and the Rise of Type 2 Diabetes in Children 113
Efficient AuFeOx Nanoclusters of Laser-Ablated Nanoparticles in Water for Cells Guiding and Surface-Enhanced Resonance Raman Scattering Imaging 113
Design and Evaluation of 223Ra-Labeled and Anti-{PSMA} Targeted {NaA} Nanozeolites for Prostate Cancer Therapy{ extemdash}Part {II}. Toxicity, Pharmacokinetics and Biodistribution 112
Effect of radiochemical modification on biodistribution of scFvD2B antibody fragment recognising prostate specific membrane antigen 111
Immunology of RIPs and their Immunotoxins, in Ribosome-inactivating Proteins: Ricin and Related Proteins 108
Dual modality imaging of PSMA-expressing prostate cancer with a new radiolabeled anti-PSMA monoclonal antibody conjugated with IRDye800CW 106
PSMA as a new target for anti-vascular therapy. Development of an in vitro model of PSMA positive endothelial cells. 106
Selective delivery of doxorubicin by novel stimuli-sensitive nano-ferritins overcomes tumor refractoriness 106
New Tc-99m-radioimmunoconjugates for pancreatic carcinoma detection 105
Induction of in vitro and in vivo NK cell cytotoxicity using high-avidity immunoligands targeting prostate-specific membrane antigen in prostate carcinoma 102
Targeting prostate cancer cells with D2B-gold Nanoparticles 101
Development and characterization of a theranostic multimodal anti-PSMA targeting agent for imaging, surgical guidance, and targeted photodynamic therapy of PSMA-expressing tumors 101
D2B antibody and its scFvD2B fragment in nanomedicine: promising tools in the theranostics of prostate cancer 101
Different Glycoforms of Prostate-Specific Membrane Antigen are intracellularly transported through their Association with Distinct Detergent-Resistant Membranes 100
Improved doxorubicin encapsulation and pharmacokinetics of ferritin-fusion protein nanocarriers bearing proline, serine, and alanine elements 99
Totale 16.119
Salva come PNG Salva come JPEG
Categoria #
all - tutte 53.561
article - articoli 39.392
book - libri 0
conference - conferenze 12.392
curatela - curatele 0
other - altro 0
patent - brevetti 945
selected - selezionate 0
volume - volumi 832
Totale 107.122
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021163 0 0 0 0 0 0 0 0 0 0 97 66
2021/2022884 79 250 14 81 37 18 16 51 20 33 74 211
2022/20231.892 147 181 171 322 136 457 74 130 200 13 46 15
2023/2024898 43 85 91 94 109 122 35 55 12 79 123 50
2024/20252.436 113 153 61 367 169 82 123 112 403 186 223 444
2025/20266.997 506 447 618 1.103 1.808 498 723 345 508 408 33 0
Totale 17.075